Brokers Issue Forecasts for R1 RCM Inc.’s FY2025 Earnings (NASDAQ:RCM)

R1 RCM Inc. (NASDAQ:RCM) – Equities research analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for shares of R1 RCM in a report issued on Thursday, June 27th. Leerink Partnrs analyst M. Cherny now forecasts that the healthcare provider will post earnings of $0.23 per share for the year, down from their previous estimate of $0.24. The consensus estimate for R1 RCM’s current full-year earnings is ($0.17) per share. Leerink Partnrs also issued estimates for R1 RCM’s FY2028 earnings at $0.88 EPS.

R1 RCM (NASDAQ:RCM) last released its quarterly earnings results on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). R1 RCM had a negative return on equity of 1.16% and a negative net margin of 1.39%. The firm had revenue of $603.90 million for the quarter, compared to analyst estimates of $612.88 million. The firm’s quarterly revenue was up 10.7% on a year-over-year basis.

RCM has been the subject of a number of other research reports. Robert W. Baird reaffirmed an “outperform” rating and set a $18.00 price target on shares of R1 RCM in a research report on Tuesday. Truist Financial reaffirmed a “hold” rating and set a $16.00 price target on shares of R1 RCM in a research report on Monday, April 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $19.00 price target on shares of R1 RCM in a research report on Friday, June 28th. KeyCorp reissued a “sector weight” rating on shares of R1 RCM in a report on Wednesday, April 10th. Finally, Guggenheim cut their price objective on R1 RCM from $17.00 to $15.00 and set a “buy” rating for the company in a report on Friday, April 5th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

R1 RCM Trading Down 13.2 %

NASDAQ:RCM opened at $10.90 on Monday. R1 RCM has a twelve month low of $8.87 and a twelve month high of $18.70. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 0.78. The business has a 50 day moving average price of $12.42 and a two-hundred day moving average price of $11.90. The company has a market cap of $4.59 billion, a P/E ratio of -136.25 and a beta of 0.85.

Institutional Investors Weigh In On R1 RCM

Large investors have recently added to or reduced their stakes in the business. Advisors Asset Management Inc. bought a new stake in R1 RCM in the 1st quarter valued at $27,000. ANTIPODES PARTNERS Ltd raised its stake in R1 RCM by 429.5% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider’s stock valued at $59,000 after acquiring an additional 4,561 shares during the period. Salem Investment Counselors Inc. bought a new stake in R1 RCM in the 4th quarter valued at $61,000. Van ECK Associates Corp increased its position in R1 RCM by 20.5% during the 4th quarter. Van ECK Associates Corp now owns 6,141 shares of the healthcare provider’s stock worth $65,000 after buying an additional 1,044 shares during the period. Finally, QRG Capital Management Inc. bought a new position in R1 RCM during the 1st quarter worth $132,000. Institutional investors own 61.10% of the company’s stock.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.